Expanding Global Support: IgA Nephropathy Foundation Launches Go Global Network to Connect and Empower IgAN Patients Worldwide. By expanding our network to Canada, we are building a stronger, more ...

Panelists discuss how immunoglobulin A (IgA) nephropathy treatment has evolved to include supportive care with optimized ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...

Panelists discuss how immunoglobulin A (IgA) nephropathy significantly impacts patients’ quality of life through chronic symptoms, treatment burden, psychological effects, and the looming threat of ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Ligand Pharmaceuticals offers biotech exposure with reduced risk through its royalty platform. Discover why its valuation now ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Aerovate Therapeutics, Inc. ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related ...